Publication: ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy.
Loading...
Identifiers
Date
2021-06-09
Authors
Bousquet, Jean
Pfaar, Oliver
Agache, Ioana
Bedbrook, Anna
Akdis, Cezmi A
Canonica, G Walter
Chivato, Tomas
Al-Ahmad, Mona
Abdul Latiff, Amir H
Ansotegui, Ignacio J
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Wiley
Metrics
Export
Abstract
Allergen immunotherapy (AIT), which involves the gradual, repeated administration of high doses of allergens to allergic patients, offers the potential for immune tolerance against reactions to natural exposures to specific allergens. AIT may lead to long-lasting remission of allergic symptoms and is the only disease-modifying intervention for IgE-mediated allergic respiratory diseases. AIT is a proven therapeutic option for the treatment of allergic rhinitis, conjunctivitis, and/or asthma, using either sublingual (SLIT) or subcutaneous (SCIT) routes.
Description
MeSH Terms
Allergens
Rhinitis, Allergic
Desensitization, Immunologic
Asthma
Immune Tolerance
Immunoglobulin E
Rhinitis, Allergic
Desensitization, Immunologic
Asthma
Immune Tolerance
Immunoglobulin E
DeCS Terms
Alérgenos
Rinitis alérgica
Enfermedades respiratorias
Desensibilización inmunológica
Asma
Inmunoglobulina E
Tolerancia inmunológica
Rinitis alérgica
Enfermedades respiratorias
Desensibilización inmunológica
Asma
Inmunoglobulina E
Tolerancia inmunológica
CIE Terms
Keywords
Allergic rhinitis, Asthma, Immunotherapy, Precision medicine
Citation
Bousquet J, Pfaar O, Agache I, Bedbrook A, Akdis CA, Canonica GW, et al. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy. Clin Transl Allergy. 2021 Jun 9;11(4):e12014